Tau and Aβ imaging, CSF measures, and cognition in Alzheimer’s disease
Open accessThe DOI matches its Crossref record; 55 of the 56 references it cites were found in a registry or an index.
Abstract
PET imaging of pathological tau correlates more closely with Alzheimer’s disease–related cognitive impairment than does imaging of β-amyloid.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These previous studies suggest that CSF tau biomarkers and Tau PET reflect different aspects of tau pathology and may become abnormal at different stages of the disease.”
From Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive tau PET in Alzheimer's disease (2020) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Elevated tau PET binding in both medial temporal lobe structures and the neocortex is strongly associated with positive amyloid PET scans and with clinical impairment across the normal aging to dementia clinical spectrum [82,130–141].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the limited data currently available, tau PET ligand binding is linearly correlated with elevated CSF P-tau [82,83,115]; however, the correlation is imperfect.”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“we examined the influence of sex to modify the well-characterized cross-sectional association between regional tau PET and global Aβ PET.14–16”
From Sex Differences in the Association of Global Amyloid and Regional Tau Deposition Measured by Positron Emission Tomography in Clinically Normal Older Adults (2019) · cites this paper as [15]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“supports recent evidence that tau may play an early pathological role in Alzheimer’s disease129–131”
From Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing (2019) · cites this paper as [131]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression shrinkage and selection via the lasso
Tibshirani, R. (1996) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1996.tb02080.x · Cited by 51,482 · cited 2×
“The family of penalized regression fit here is the elastic net penalty (27): the L1 penalty component enforces sparsity (that is, many bs will be identically 0, not included in the model) (26), whereas the L2 penalty allows highly correlated variables to enter the model simultaneously (27).”
Regularization and Variable Selection Via the Elastic Net
Zou, H., & Hastie, T. (2005) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.1467-9868.2005.00503.x · Cited by 20,957
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Self-citationNeuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 3×
“The specificity of this relationship strengthens the argument that the identified relationships are disease-specific: elevated tau in the CSF is associated with tau deposition within regions known to be sensitive to AD-related tauopathy (2).”
InfluentialThe Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Self-citationAlzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155 · cited 2×
“Overlap with respect to CDR status likely represents the variable relationship between pathological burden and cognitive symptoms often attributed to differences in host factors, for example, cognitive reserve (8, 23).”
Self-citationOverdependence on degraded gist memory in Alzheimer's disease.
Gallo, D. A., Shahid, K. R., Olson, M. A., Solomon, T. M., Schacter, D. L., & Budson, A. E. (2006) · Neuropsychology · doi:10.1037/0894-4105.20.6.625 · Cited by 4,732
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496 · cited 2×
“The Aβ imaging literature has grown over the past decade (4), whereas tau imaging is a relatively new addition to the field.”
Jack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Research works printed but not linked: 1
- 50. Roussas GG A First Course in Mathematical Statistics Addison-Wesley Pub. Co. Reading, MA 1973
Cited by
Items 401–500 of 736
Provost, K., Joie, R. L., Strom, A., Iaccarino, L., Edwards, L., Mellinger, T. J., Pham, J. Q., Baker, S. L., Miller, B. L., Jagust, W. J., et al. (2021) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x211001216 · Cited by 18
Nanoplasmonic assay platforms for reproducible SERS detection of Alzheimer's disease biomarker
Dang, H., Joung, Y., Jeong, C., Jeon, C. S., Pyun, S. H., Park, S., & Choo, J. (2023) · Bulletin of the Korean Chemical Society · doi:10.1002/bkcs.12679 · Cited by 17
Long COVID could become a widespread post-pandemic disease? A debate on the organs most affected
Ferrara, F., Zovi, A., Masi, M., Langella, R., Trama, U., Boccellino, M., & Vitiello, A. (2023) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-023-02417-5 · Cited by 23
Tau: a biomarker of Huntington’s disease
Lepinay, E., & Cicchetti, F. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02230-9 · Cited by 19
Kim, S., Shin, S. J., Nam, Y., Park, Y. H., Kim, B., Park, H. H., Kumar, V., Yoo, D., Lee, Y. Y., Hoe, H., et al. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.130516 · Cited by 20
Data‐driven decomposition and staging of flortaucipir uptake in Alzheimer's disease
Earnest, T., Bani, A., Ha, S. M., Hobbs, D. A., Kothapalli, D., Yang, B., Lee, J. J., Benzinger, T. L. S., Gordon, B. A., Sotiras, A., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13769 · Cited by 19
Self-citationMohammadi, S., Ghaderi, S., & Fatehi, F. (2024) · Aging Medicine · doi:10.1002/agm2.12363 · Cited by 20
“Advances in biomarker discovery and diagnostics for alzheimer’s disease”
Bhatia, V., Chandel, A., Minhas, Y., & Kushawaha, S. K. (2025) · Neurological Sciences · doi:10.1007/s10072-025-08023-y · Cited by 21
Age-Related Differences in the Human Hippocampus: Behavioral, Structural and Functional Measures
Grady, C. L., & Ryan, J. D. (2017) · Springer eBooks · doi:10.1007/978-3-319-50406-3_7 · Cited by 27
New treatment modalities in Alzheimer's disease
Köseoğlu, E. (2019) · World Journal of Clinical Cases · doi:10.12998/wjcc.v7.i14.1764 · Cited by 19
Pourhamzeh, M., Joghataei, M. T., Mehrabi, S., Ahadi, R., Hojjati, S. M. M., Fazli, N., Nabavi, S. M., Pakdaman, H., & Shahpasand, K. (2020) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-020-00906-2 · Cited by 20
RetractedKang, M. S., Shin, M., Ottoy, J., Aliaga, A., Mathotaarachchi, S. S., Quispialaya, K. M., Pascoal, T. A., Collins, D. L., Chakravarty, M. M., Mathieu, A. P., et al. (2021) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x211035625 · Cited by 19
Retromer dysfunction at the nexus of tauopathies
Carosi, J. M., Denton, D., Kumar, S., & Sargeant, T. J. (2021) · Cell Death & Differentiation · doi:10.1038/s41418-020-00727-2 · Cited by 16
Illustrated Neuropathologic Diagnosis of Alzheimer’s Disease
Doher, N., Davoudi, V., Magaki, S., Townley, R. A., Haeri, M., & Vinters, H. V. (2023) · Neurology International · doi:10.3390/neurolint15030054 · Cited by 16
Kapasi, A., James, B. D., Yu, L., Sood, A., Arvanitakis, Z., Bennett, D. A., Boyle, P. A., & Schneider, J. A. (2025) · Neurology · doi:10.1212/wnl.0000000000214004 · Cited by 22
Moscoso, A., Grothe, M. J., Schöll, M., & Initiative, A. D. N. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05195-5 · Cited by 17
Roles of Exosomes and Exosomal MicroRNAs in Postoperative Sleep Disturbance
Gu, X., & Zhu, J. (2021) · Nature and Science of Sleep · doi:10.2147/nss.s310351 · Cited by 16
Xia, T., Zhang, J., Guo, Y.-X., Jiang, Y., Qiao, F., Li, K., Wang, N., Han, T., & Xin, H. (2023) · Molecules · doi:10.3390/molecules28020583 · Cited by 18
“Aβ deposition can cause neurotoxicity and oxidative stress, which leads to wide neurodegeneration [14].”
BackgroundNovel monoclonal antibodies targeting the microtubule-binding domain of human tau
Croft, C. L., Moore, B. D., Ran, Y., Chakrabarty, P., Levites, Y., Golde, T. E., & Giasson, B. I. (2018) · PLoS ONE · doi:10.1371/journal.pone.0195211 · Cited by 16
Estimates of age-related memory decline are inflated by unrecognized Alzheimer's disease
Harrington, K., Schembri, A. J., Lim, Y. Y., Dang, C., Ames, D. J., Hassenstab, J. J., Laws, S. M., Rainey‐Smith, S. R., Robertson, J. S., Rowe, C. C., et al. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.06.005 · Cited by 19
Self-citationSullivan, K., Liu, A., Chang, C.-C. H., Cohen, A. D., Lopresti, B. J., Minhas, D. S., Laymon, C. M., Klunk, W. E., Aizenstein, H. J., Nadkarni, N. K., et al. (2020) · Brain Imaging and Behavior · doi:10.1007/s11682-020-00334-2 · Cited by 16
“In our current findings, however, tau PET was not associated with age, consistent with some reports (Brier et al. 2016; Schwarz et al. 2016), but in contrast to age associations in others (Johnson et al. 2016; Lowe et al. 2018).”
ResultSelvan, S. T., Ravichandar, R., Ghosh, K. K., Mohan, A., Mahalakshmi, P., Gulyás, B. Z., & Padmanabhan, P. (2020) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2020.213659 · Cited by 17
Pursuit of precision medicine: Systems biology approaches in Alzheimer's disease mouse models
Gurdon, B., & Kaczorowski, C. C. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105558 · Cited by 17
Yang, Q., Chen, K., Zhang, H., Zhang, W., Gong, C., Zhang, Q., Liu, P., Sun, T., Xu, Y., Qian, X., et al. (2019) · Neuroscience Bulletin · doi:10.1007/s12264-019-00343-2 · Cited by 18
Morderer, D., Wren, M. C., Liu, F., Kouri, N., Maistrenko, A., Khalil, B., Pobitzer, N., Salemi, M., Phinney, B. S., Bu, G., et al. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00817-0 · Cited by 23
Towards pharmacological prevention of Alzheimer disease
Llibre‐Guerra, J. J., McDade, E., Schindler, S. E., Clifford, D. B., Supnet, C. B., Atri, A., & Bateman, R. J. (2025) · Nature Reviews Neurology · doi:10.1038/s41582-025-01154-y · Cited by 20
“Subsequently, the development of radiotracers that bind to Aβ plaques and tau neurofibrillary tangles enabled PET imaging of the burden and regional distribution of AD pathology in the brain 4,5,30 .”
Association of Tau Pathology With Clinical Symptoms in the Subfields of Hippocampal Formation
Ge, X., Zhang, D., Qiao, Y., Zhang, J., Xu, J., & Zheng, Y. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.672077 · Cited by 17
“The presence of abnormal amyloid status was regarded as the ‘disease state’ to determine if the subject is during the Alzheimer’s pathologic process (Brier et al., 2016).”
BackgroundInfluentialQiao, Z., Wang, G., Zhao, X. B., Wang, K., Fan, D., Chen, Q., & Ai, L. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.841942 · Cited by 18
Sex and gender differences in dementia
Salwierz, P., Davenport, C., Sumra, V., Iulita, M. F., Ferretti, M. T., & Tartaglia, M. C. (2022) · International review of neurobiology · doi:10.1016/bs.irn.2022.07.002 · Cited by 17
Horie, K., Li, Y., Barthélemy, N. R., Gordon, B. A., Hassenstab, J. J., Benzinger, T. L. S., Fagan, A. M., Morris, J. C., Karch, C. M. M., Xiong, C., et al. (2023) · Annals of Neurology · doi:10.1002/ana.26620 · Cited by 18
Self-citationAntioxidant Potential of Xanthohumol in Disease Prevention: Evidence from Human and Animal Studies
Piekara, J., & Piasecka‐Kwiatkowska, D. (2024) · Antioxidants · doi:10.3390/antiox13121559 · Cited by 16
Bin1 antibody lowers the expression of phosphorylated Tau in Alzheimer's disease
Thomas, S., Hoxha, K., Tran, A., & Prendergast, G. C. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.29142 · Cited by 17
“Deposition of Tau in the temporal lobe of the brain more closely track dementia status and is a better predictor of cognitive performance than Aβ deposition in any other region of the brain.(31) In recent years, a human gene called BIN1 has emerged as one of the most important human genes in affecting the incidence of…”
BackgroundChotipanich, C., Monchaya, N., Kunawudhi, A., Promteangtrong, C., Boonkawin, N., & Jantarato, A. (2020) · Molecular Imaging · doi:10.1177/1536012120947582 · Cited by 15
Wong, H., Buck, J. M., Borski, C., Pafford, J., Keller, B. N., Milstead, R. A., Hanson, J. L., Stitzel, J. A., & Hoeffer, C. A. (2022) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-022-09444-y · Cited by 16
Updates on pharmacological treatment for Alzheimer’s disease
Tipton, P. W. (2024) · Neurologia i Neurochirurgia Polska · doi:10.5603/pjnns.96286 · Cited by 18
Wang, X., Sundermann, E. E., Buckley, R. F., Banks, S. J., & the A4 Study Team (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13432 · Cited by 16
“13,29,30 Our results also support the link between greater tau pathology and poorer cognitive performance in preclinical AD.”
Zheng, L., Rubinski, A., Denecke, J., Luan, Y., Smith, R. A., Strandberg, O. T., Stomrud, E., Ossenkoppele, R., Svaldi, D. O., Higgins, I. A., et al. (2023) · Annals of Neurology · doi:10.1002/ana.26818 · Cited by 17
Cell-free RNA signatures predict Alzheimer’s disease
Cisterna‐García, A., Beric, A., Ali, M., Pardo, J. A., Chen, H., Fernández, M. V., Norton, J. B., Gentsch, J., Bergmann, K., Budde, J., et al. (2023) · iScience · doi:10.1016/j.isci.2023.108534 · Cited by 14
Self-citationDoering, S., McCullough, A. A., Gordon, B. A., Chen, C. D., McKay, N. S., Hobbs, D. A., Keefe, S., Flores, S. E., Scott, J., Smith, H. D., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105080 · Cited by 24
Self-citationChang, Y. Z., Liu, J., Xu, X., Sun, S., Zhang, J., Zhang, X., Lu, G., Xiao, S., Cao, Y., Wu, R., et al. (2024) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-024-07016-x · Cited by 15
“Brier et al., [42] used multivariate analysis to identify unique disease-related topographic patterns of Aβ and tau aggre - gation.”
Alzheimer’s Disease and Other Dementias: An Introduction
Blank, R. H. (2018) · Springer eBooks · doi:10.1007/978-981-13-0656-3_1 · Cited by 18
Allison, S. L., Jonaitis, E. M., Koscik, R. L., Hermann, B. P., Mueller, K. D., Cary, R. P., Ma, Y., Rowley, H. A., Carlsson, C. M., Asthana, S., et al. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2021.01.030 · Cited by 16
“specific to AD are those reflecting beta-amyloid deposition and the formation of neurofibrillary tangles (NFTs) (Betthauser et al., 2018; Betthauser et al., 2019; Brier et al., 2016; Jack et al., 2018; Klunk et al., 2004; Roe et al., 2013; Strozyk, Blennow, White, & Launer, 2003; Tapiola et al., 2009; Villemagne, Doré…”
BackgroundNetwork interdigitations of Tau and amyloid‐beta deposits define cognitive levels in aging
Kim, C. M., Montal, V., Diez, I. P., Orwig, W., Initiative, A. D. N., & Sepulcre, J. (2021) · Human Brain Mapping · doi:10.1002/hbm.25350 · Cited by 13
“In fact, it is now known that regions of A β and tau accumulation show network bonds, even without spatial overlapping between them (Brier et al., 2016;Iaccarino et al., 2018; Sepulcre et al., 2016).”
AD molecular: Imaging tau aggregates with positron emissions tomography
Betthauser, T. J. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.07.007 · Cited by 15
Vasilevskaya, A., Taghdiri, F., Multani, N., Anor, C. J., Misquitta, K., Houle, S., Burke, C., Tang‐Wai, D. F., Lang, A. E., Fox, S. H., et al. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00574 · Cited by 17
Hassenstab, J. J., Nicosia, J., LaRose, M., Aschenbrenner, A. J., Gordon, B. A., Benzinger, T. L. S., Xiong, C., & Morris, J. C. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00894-5 · Cited by 13
“As expected, and consistent with prior work in this cohort [41, 42], more robust relationships were seen in CDR 0.”
ResultSelf-citationGe, X., Initiative, A. D. N., Qiao, Y., Choi, J., Raman, R., Ringman, J. M., & Shi, Y. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215555 · Cited by 14
Comparison Between 18F-Florapronol and 18F-Florbetaben Imaging in Patients With Cognitive Impairment
Baik, K., Jeon, S., Park, M., Lee, Y., Lee, P. H., Sohn, Y. H., & Ye, B. S. (2023) · Journal of Clinical Neurology · doi:10.3988/jcn.2022.0207 · Cited by 14
Payne, T., Taylor, J., Casey, C., Kunkel, D., Parker, M., Blennow, K., Zetterberg, H., Pearce, R. A., Lennertz, R. C., & Sanders, R. (2023) · British Journal of Anaesthesia · doi:10.1016/j.bja.2023.01.020 · Cited by 15
Zhang, Q., Fan, C., Wang, L., Li, T., Wang, M., Han, Y., Jiang, J., Initiative, A. F. T. A. D. N., Weiner, M. W., Aisen, P. S. S., et al. (2023) · GeroScience · doi:10.1007/s11357-023-00897-0 · Cited by 16
Self-citationRani, N., Alm, K. H., Corona-Long, C. A., Speck, C. L., Soldan, A., Pettigrew, C. A., Zhu, Y., Albert, M., & Bakker, A. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1272946 · Cited by 14
Jia, W., Lin, H., Yang, M., Dai, Y.-L., Ding, Y., Xu, W.-S., Wang, S.-N., Cao, Y., Liang, S., Wang, Z., et al. (2024) · Journal of Chinese Integrative Medicine · doi:10.1016/j.joim.2024.08.002 · Cited by 14
Shen, X., Kuo, K., Yang, Y., Li, H., Chen, S., Cui, M., Tan, L., Dong, Q., Yu, J., & Initiative, A. D. N. (2021) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12198 · Cited by 16
Onaolapo, A. Y., Ojo, F. O., Adeleye, O. O., Falade, J., & Onaolapo, O. J. (2023) · Current Diabetes Reviews · doi:10.2174/1573399819666230102141154 · Cited by 15
Kim, H. J., Kim, R. E. Y., Kim, S., Lee, S. K., Lee, H. W., & Shin, C. (2023) · SLEEP · doi:10.1093/sleep/zsad108 · Cited by 14
Tau: A Common Denominator and Therapeutic Target for Neurodegenerative Disorders
Maxan, A., & Cicchetti, F. (2018) · Journal of Experimental Neuroscience · doi:10.1177/1179069518772380 · Cited by 16
Yao, W., Initiative, A. D. N., Zhang, X., Zhao, H., Xu, Y., & Bai, F. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220475 · Cited by 10
Mapping the association between tau-PET and Aβ-amyloid-PET using deep learning
Ruwanpathirana, G. P., Williams, R. C., Masters, C. L., Rowe, C. C., Johnston, L. A., & Davey, C. E. (2022) · Scientific Reports · doi:10.1038/s41598-022-18963-6 · Cited by 13
Acharya, N. K., Grossman, H. C., Clifford, P. M., Levin, E. C., Light, K., Choi, H.-N., Swanson, R. L., Kosciuk, M. C., Venkataraman, V., Libon, D. J., et al. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231028 · Cited by 16
Day, G. S. (2024) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000001507 · Cited by 15
Cell-specific copper dyshomeostasis mechanism in Alzheimer’s disease
Okafor, M., Faller, P., & Vitale, N. (2025) · Translational Neurodegeneration · doi:10.1186/s40035-025-00504-6 · Cited by 18
Roe, C. M., Babulal, G. M., Mishra, S., Gordon, B. A., Stout, S. H., Ott, B. R., Carr, D. B., Ances, B. M., Morris, J. C., & Benzinger, T. L. S. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170521 · Cited by 13
“Data from the 50–70-min post IV window 127 were converted to standardized uptake value ratios 128 (SUVRs) using the cerebellar cortex as a reference 129 [17, 18].”
Self-citationMa, W., Chen, A.-F., Xie, X., & Huang, Y. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108342 · Cited by 13
Shu, H., Gu, L., Yang, P., Lucas, M. V., Gao, L., Zhang, H., Zhang, H., Xu, Z., Wu, W., Li, L., et al. (2021) · NeuroImage Clinical · doi:10.1016/j.nicl.2021.102572 · Cited by 15
“EM deficits are associated with abnormalities of established AD biomarkers, including β-amyloid or tau protein deposition in the medial temporal lobe (MTL) (Brier et al., 2016), reduced entorhinal volume (Rodrigue and Raz, 2004), and cortical hypometabolism (Nishi et al.”
InfluentialMalik, R., Kalra, S., Pooja, Singh, G., Meenu, M., Gahlot, V., Kajal, A., & Rimpy (2023) · Brain Research · doi:10.1016/j.brainres.2023.148616 · Cited by 14
Heston, M. B., Teague, J. P., Cody, K. A., Deming, Y. K., Chavez, E. R. D., Morse, J., Chin, N. A., Engelman, C. D., Chappell, R. J., Langhough, R. E., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70551 · Cited by 14
“7,54,55 While initially intuitive that high amyloid burden accelerates progression from T + to dementia, this is also somewhat counterintuitive because higher amyloid at T + translates to individuals having a longer A + to T + time.”
Chow, T. E., Veziris, C. R., Mundada, N. S., Martinez-Arroyo, A. I., Kramer, J. H., Miller, B. L., Rosen, H. J., Gorno‐Tempini, M. L., Rankin, K. P., Seeley, W. W., et al. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230367 · Cited by 14
Mathematical modelling of dendritic complexity mechanism in Alzheimer’s disease
Kumari, R., Goel, S., & Das, S. (2023) · AIP conference proceedings · doi:10.1063/5.0163400 · Cited by 12
Role of Tau protein in long COVID and potential therapeutic targets
Marwaha, B. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1280600 · Cited by 13
Quan, Y., Li, X., Pang, L., Deng, H., Chen, F., Lee, J. J., Quan, Z., Liu, P., Guo, H., & Shen, Q. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106977 · Cited by 11
Hu, N., Hu, Z., Ondrejčák, T., Yu, P., Zhang, Y., Yang, Y., Klyubin, I. V., Kennelly, S., & Rowan, M. J. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.360166 · Cited by 11
“Although tau mainly exists in the intracellular compartment, relatively high levels of both total tau and p-tau are also present in CSF of AD patients (Brier et al., 2016).”
BackgroundAlzheimer Disease Biomarkers in Clinical Practice: A Blood-Based Diagnostic Revolution
Paczynski, M., & Day, G. S. (2022) · Journal of Primary Care & Community Health · doi:10.1177/21501319221141178 · Cited by 13
Warpechowski, M., Warpechowski, J. J., Kulczyńska‐Przybik, A., & Mroczko, B. (2022) · Medical Science Monitor · doi:10.12659/msm.938826 · Cited by 15
Velez, J. I., Lopera, F. J., Creagh, P. K., Piñeros-Hernández, L. B., Das, D., Cervantes-Henríquez, M. L., Acosta-López, J. E., Isaza-Ruget, M. A., Espinosa, L. G., Easteal, S., et al. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1298-z · Cited by 14
Hays, C. C., Zlatar, Z. Z., Meloy, M. J., Osuna, J., Liu, T. T., Galasko, D. R., & Wierenga, C. E. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190504 · Cited by 12
Wiratpruk, N., Noor, A., McLean, C., Donnelly, P. S., & Barnard, P. J. (2020) · Dalton Transactions · doi:10.1039/c9dt04687a · Cited by 12
Systems genetics identifies modifiers of Alzheimer’s disease risk and resiliencePreprint
Neuner, S. M., Hohman, T. J., Richholt, R., Bennett, D. A., Schneider, J. A., Jager, P. L. D., Huentelman, M. J., O’Connell, K. M. S., & Kaczorowski, C. C. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/225714 · Cited by 11
“In addition, as tau has been seen to be more strongly associated with cognitive function in AD than other pathologies (Brier et al., 2016), the AD-BXD panel may provide new opportunities to study the relationship between tau, amyloid, and cognitive function in the context of genetic diversity.”
BackgroundBeyond the Amyloid Hypothesis of Alzheimer’s Disease: Tau Pathology Takes Center Stage
Lindsley, C. W., & Hooker, J. M. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00610 · Cited by 11
Night‐to‐night variability in sleep and amyloid beta burden in normal aging
Jouvencel, A., Baillet, M., Meyer, M., Dilharreguy, B., Lamare, F., Pérès, K., Helmer, C., Dartigues, J., Amieva, H., Mayo, W., et al. (2023) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12460 · Cited by 12
Hsieh, C.-H., Ko, C.-A., Liang, C., Yeh, P.-K., Tsai, C., Tsai, C., Lin, G., Lin, Y., Tsai, M., & Yang, F. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1389595 · Cited by 12
Ban, S. Y., Nam, Y., Do, T. T., Kim, B., Shin, S. J., Nguyen, M. T. T., Kim, J., Moon, M., & Park, J. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.117895 · Cited by 15
Hojjati, S. H., Chiang, G. C.-Y., Butler, T., Chen, K., Khalafi, M., Yazdi, B. G., Foldi, N. S., Nayak, S., de Leon, M. J., Li, Y., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70153 · Cited by 12
Biologics as Therapeutical Agents Under Perspective Clinical Studies for Alzheimer’s Disease
Li, H., Shen, X., Zhang, B., & Zhu, Z. (2025) · Molecules · doi:10.3390/molecules30173479 · Cited by 12
“Tau-targeted immunotherapy has emerged as a key strategy in AD, driven by the observation that tau pathology correlates more closely with cognitive impairment than A β deposition [169].”
Moore, E. E., Liu, D., Pechman, K. R., Acosta, L. M. Y., Bell, S. P., Davis, L. T., Blennow, K., Zetterberg, H., Landman, B. A., Schrag, M., et al. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00139 · Cited by 12
Li, K., Wang, S., Luo, X., Zeng, Q., Jiaerken, Y., Xu, X., Wang, C., Liu, X., Li, Z., Zhao, S., et al. (2020) · Cerebral Cortex · doi:10.1093/cercor/bhaa162 · Cited by 10
Clear‐headed into old age: Resilience and resistance against brain aging—A PET imaging perspective
Hoenig, M. C., & Drzezga, A. E. (2022) · Journal of Neurochemistry · doi:10.1111/jnc.15598 · Cited by 9
“…and staging marker, as it is more closely associated with neurodegeneration and cognitive decline than amyloid PET (Bischof et al., 2016; Brier et al., 2016; Bucci et al., 2021; Chen et al., 2021; La Joie et al., 2018; Ossenkoppele et al., 2016; Pontecorvo et al., 2017; Scholl et al.,…”
BackgroundCerebral blood flow, tau imaging, and memory associations in cognitively unimpaired older adults
Weigand, A. J., Hamlin, A. M., Breton, J., & Clark, A. L. (2022) · Cerebral Circulation - Cognition and Behavior · doi:10.1016/j.cccb.2022.100153 · Cited by 10
Emmerson, J. T., Carmo, S. D., Liu, Y., Shalhoub, A., Ai, L., Bonomo, Q., Malcolm, J. C., Breuillaud, L., & Cuello, A. C. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106227 · Cited by 13
ZCCHC17 Modulates Neuronal RNA Splicing and Supports Cognitive Resilience in Alzheimer's Disease
Bartosch, A. M. W., Youth, E. H. H., Hansen, S., Wu, Y., Buchanan, H. M., Kaufman, M. E., Xiao, H., Koo, S. Y., Ashok, A., Sivakumar, S., et al. (2023) · Journal of Neuroscience · doi:10.1523/jneurosci.2324-22.2023 · Cited by 10
The relationship between CSF biomarkers and cerebral metabolism in early-onset Alzheimer’s disease
Jaillard, A., Vanhoutte, M., Maureille, A., Schraen‐Maschke, S., Skrobala, E., Delbeuck, X., Rollin‐Sillaire, A., Pasquier, F., Bombois, S., & Semah, F. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4113-1 · Cited by 12
Flortaucipir (tau) PET in LGI1 antibody encephalitis
Day, G. S., Gordon, B. A., McCullough, A. A., Bucelli, R. C., Perrin, R. J., Benzinger, T. L. S., & Ances, B. M. (2021) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51297 · Cited by 12
Self-citationGreater tau pathology is associated with altered predictive coding
Gjini, K., Casey, C., Tanabe, S., Bo, A., Parker, M., White, M., Kunkel, D., Lennertz, R., Pearce, R. A., Betthauser, T., et al. (2022) · Brain Communications · doi:10.1093/braincomms/fcac209 · Cited by 9
“Tau pathology is considered to accumulate once amyloid burden is present, and level of tau burden correlates with cognitive decline 6 and increased excitability of neuronal circuits through disinhibition (loss of GABAergic interneuron driven control of signalling).”
Kapadia, A. N., Bilimoria, K., Desai, P., Grist, J. T., Heyn, C., Maralani, P. J., Symons, S. P., & Zaccagna, F. (2023) · Journal of Clinical Neurology · doi:10.3988/jcn.2022.0088 · Cited by 11
Edwards, L., Initiative, A. D. N., Thomas, K. R., Weigand, A. J., Edmonds, E. C., Clark, A. L., Walker, K. S., Brenner, E. K., Nation, D. A., Maillard, P., et al. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221209 · Cited by 9
Assessment of individual retinal layer thickness and vascular changes in Alzheimer’s disease
Zabel, P., Przekoracka‐Krawczyk, A., Jaworski, D., Zabel, K., Suwała, K., Gębska‐Tołoczko, M., Kucharski, R., & Kałuzny, J. J. (2025) · Scientific Reports · doi:10.1038/s41598-025-02377-1 · Cited by 11
Weigand, A. J., Ortiz, G., Walker, K. S., Galasko, D. R., Bondi, M. W., & Thomas, K. R. (2023) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2022.10.016 · Cited by 10
Kammula, S. V., Tripathi, S., Wang, N., Dawson, V. L., Dawson, T. M., & Mao, X. (2023) · Ageing and Neurodegenerative Diseases · doi:10.20517/and.2023.20 · Cited by 16
Abdullah, M., Ruan, Z., Ikezu, S., & Ikezu, T. (2024) · Journal of Extracellular Biology · doi:10.1002/jex2.155 · Cited by 10
Linking Amyloid-β and Tau Deposition in Alzheimer Disease
Vemuri, P., & Schöll, M. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2017.0323 · Cited by 9
Novel Key Players in the Development of Tau Neuropathology: Focus on the 5-Lipoxygenase
Lauretti, E., & Praticò, D. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-179931 · Cited by 10
“Notably, both brain imaging studies and CSF measures in AD patients have confirmed that the extent of tau neuropathology strongly correlates with the levels of dementia and memory loss [14].”
Metadata
- Authors
- Brier, M. R., Gordon, B., Friedrichsen, K., McCarthy, J., Stern, A., Christensen, J., Owen, C., Aldea, P., Su, Y., Hassenstab, J., Cairns, N. J., Holtzman, D. M., Fagan, A. M., Morris, J. C., Benzinger, T. L. S., & Ances, B. M.
- Affiliations
- Washington University in St. Louis (US)
- Corresponding author
- Benzinger, Tammie L. S.
- Ances, Beau M.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2016-05-11
- Volume
- 8
- Issue
- 338
- Pages
- 338ra66-338ra66
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC5267531
- OpenAlex
- W2353776455
- Cited by
- 734
- References
- 56
- Citations by year
- 2026: 40 · 2025: 60 · 2024: 58 · 2023: 69 · 2022: 64 · 2021: 90 · 2020: 101 · 2019: 80 · 2018: 73 · 2017: 75 · 2016: 23
- FWCI
- 74.35
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion, cc-by)
- PubMed Central (acceptedVersion, cc-by)
- Open Scholarship Institutional Repository (Washington University in St. Louis) (submittedVersion)
- Funders
- NIH (P50AG05681, P01AG003991, P01AG026276, 5P30NS048056, 2UL1TR000448, 5RO1AG04343404)
- NSF (DMS1300280)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- Alzheimer's disease, tau PET imaging, cerebrospinal fluid tau, temporal lobe, preclinical Alzheimer's disease, cognitive performance, disease progression, neurofibrillary tangles, neuritic plaques
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Brain, Cognition, Female, Humans, Male, Peptide Fragments, Amyloid beta-Peptides, tau Proteins, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.